Related references
Note: Only part of the references are listed.Rationale and design of the ETN-STEP (Early administration of Tirofiban in mid to high risk patients with non-ST elevation acute coronary syndrome referred for percutaneous coronary intervention) project: A multi-center, randomized, controlled clinic trial in Chinese patients
Jian-Ping Li et al.
JOURNAL OF GERIATRIC CARDIOLOGY (2012)
Failed Recovery from Thrombolysis Is Predicted by the Initial Diffusion Weighted Imaging Lesion
Ruediger J. Seitz et al.
CEREBROVASCULAR DISEASES (2011)
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes
Matthias Schwenkglenks et al.
VALUE IN HEALTH (2011)
Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome
Marco Valgimigli
EUROPEAN HEART JOURNAL SUPPLEMENTS (2010)
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes
Robert A. Harrington et al.
CHEST (2008)
Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions - The EVEREST trial
L Bolognese et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial
EM Ohman et al.
AMERICAN HEART JOURNAL (2005)
Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction
H Steen et al.
AMERICAN HEART JOURNAL (2005)
Share Paper
